Abstracts Archive - Page 1235 of 2425 - ACR Meeting Abstracts

Abstract Number: 442 • 2017 ACR/ARHP Annual Meeting
Early Treatment with Hydroxychloroquine Is Associated with Better Long-Term Outcomes in a Group of Hispanic Patients with Rheumatoid Arthritis
Franchesca Cruz-Pérez¹, Mariangelí Arroyo-Ávila¹, Ruth Fred-Jiménez², Naydi Pérez-Ríos³, Noelia Rodríguez-Pérez¹, Grissel Ríos⁴ and Luis M. Vilá⁵, ¹Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, PR, ²Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico, ³Puerto Rico Clinical and Translational Research Consortium, University of Puerto Rico Medical Sciences Campus, San Juan, PR, ⁴Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, PR, ⁵Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico
Background/Purpose: Hydroxychloroquine (HCQ) has a disease-modifying effect in rheumatoid arthritis (RA) patients but also it is associated with improved lipid profile, and decreased risk for…
Abstract Number: 443 • 2017 ACR/ARHP Annual Meeting
Methotrexate Treatment Strategies in an Early Rheumatoid Arthritis Cohort
Sasha Bernatsky¹, Orit Schieir², Cristiano S. Moura³, Marie-France Valois⁴, Susan J. Bartlett⁵, Carol A Hitchon⁶, Janet E. Pope⁷, Gilles Boire⁸, Boulos Haraoui⁹, Edward C. Keystone¹⁰, Diane Tin¹¹, Carter Thorne¹² and Vivian P. Bykerk¹³, ¹Divisions of Rheumatology and Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ²Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, ³1Division of Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ⁴McGill University, Montreal, QC, Canada, ⁵Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁶University of Manitoba, Winnipeg, MB, Canada, ⁷Department of Medicine, Division of Rheumatology, University of Western Ontario, St Joseph's Health Care, London, ON, Canada, ⁸Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁹Institute de Rheumatologie, Montreal, QC, Canada, ¹⁰Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, ¹¹The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹²University of Toronto, Newmarket, ON, Canada, ¹³2-005, Mt Sinai Hospital, Toronto, ON, Canada
Background/Purpose: Methotrexate (MTX) is recommended as part of initial therapy in early RA, but practices range widely. The objective of this analysis was to describe…
Abstract Number: 444 • 2017 ACR/ARHP Annual Meeting
Do Rheumatoid Arthritis Clinical Disease Activity Index Based Treat-to-Target Treatment Decisions Always Correspond to Usual Care Treatment Decisions at Point of Care?
Rajesh Gopalarathinam¹, Maryann Kimoto² and Tarun S. Sharma³, ¹Internal Medicine, Allegheny General Hospital- Allegheny Health Network, Pittsburgh, PA, ²Internal Medicine, Allegheny General Hospital - Allegheny Health Network, Pittsburgh, PA, ³Rheumatology, Lupus Center of Excellence, Allegheny Health Network, Pittsburgh, PA
Variables Concordant decisions (71%, n=22) Discordant decisions (29%, n=9) PtGA >50% of CDAI calculation (68%, n=21) Age (mean, years) 49 51 48 Sex (%, females)…
Abstract Number: 445 • 2017 ACR/ARHP Annual Meeting
FLARE-RA Instrument Detects RA Flares Independent of Disease Activity
Taysir G. Mahmoud¹, Michelle Frits², Christine Iannaccone³, Gabriela Maica⁴, Vivian P. Bykerk⁵, Michael Weinblatt⁶ and Nancy A. Shadick⁷, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁴Department of Rheumatology, Allergy, and Immunology, Brigham and Women's Hospital, Boston, MA, ⁵2-005, Mt Sinai Hospital, Toronto, ON, Canada, ⁶Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁷Rheumatology Immunology & Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Clinicians often associate the occurrence of a recent rheumatoid arthritis (RA) flare with an increase in overall disease activity. However, previous studies have shown…
Abstract Number: 446 • 2017 ACR/ARHP Annual Meeting
Methotrexate Use and Fatigue in Rheumatoid Arthritis Patients: Results from a National Patient Registry
Huifeng Yun¹, Shuo Yang², W. Benjamin Nowell³, Cooper Filby¹, Lang Chen¹ and Jeffrey R. Curtis⁴, ¹University of Alabama at Birmingham, Birmingham, AL, ²Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Global Healthy Living Foundation, Upper Nyack, NY, ⁴Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Methotrexate (MTX), a synthetic disease-modifying antirheumatic drug (DMARD), is the most commonly used medication for rheumatoid arthritis (RA). Considerable variations between patients taking MTX…
Abstract Number: 447 • 2017 ACR/ARHP Annual Meeting
Tocilizumab Had Acceptable Retention Rate in Both Randomized Controlled Trials and Observational Studies: Systematic Review of Rheumatoid Arthritis
Levent Kilic¹, Orhan Kucuksahin², Zeynep Ozbalkan³, Cemal Bes⁴, Veli Yazisiz⁵, Ayten Yazici⁶, Dilek Solmaz⁷, Timucin Kasifoglu⁸ and Umut Kalyoncu⁹, ¹Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ²Rheumatology, Yildirim Beyazit University Faculty of Medicine, Ankara, Turkey, ³Rheumatology, Ankara Numune Education and Research Hospital, Ankara, Turkey, ⁴Rheumatology, Bakırköy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey, ⁵Rheumatology, Akdeniz University Faculty of Medicine, Ankara, Turkey, ⁶Department of Rheumatology, Kocaeli University, Faculty of Medicine, Kocaeli, Turkey, ⁷Rheumatology, Katip Çelebi University Faculty of Medicine, İzmir, Turkey, ⁸Rheumatology, Eskisehir Osmangazi University Faculty of Medicine, Eskişehir, Turkey, ⁹Department of Internal Medicine, Divison of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey
Background/Purpose: In general, retention rate in biological DMARDs represent both efficacy and safety. Tocilizumab (TOC) is a humanized monoclonal antibody that binds to the interleukin-6…
Abstract Number: 448 • 2017 ACR/ARHP Annual Meeting
Predicting Remission at 6 Months in Early Rheumatoid Arthritis Treated with Conventional Synthetic Dmards
Michael D Wiese¹, Robert Metcalf², Mihir D Wechalekar³, Llew Spargo², Leah McWilliams⁴, Michael James^4,5, Catherine Hill⁶ and Susanna Proudman⁷, ¹School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia, ²Rheumatology Unit, Royal Adelaide Hospital, South Australia, Adelaide, Australia, ³Royal Adelaide Hospital, Adelaide, Australia, ⁴Department of Rheumatology, Royal Adelaide Hospital, Adelaide, Australia, ⁵Department of Medicine, University of Adelaide, Adelaide, Australia, ⁶The Queen Elizabeth Hospital, Adelaide, Australia, ⁷University of Adelaide, Adelaide, Australia
Background/Purpose: Initial treatment of RA with triple csDMARD therapy can achieve remission in a proportion of patients. Others respond poorly yet must wait at least…
Abstract Number: 449 • 2017 ACR/ARHP Annual Meeting
Medical Bugs for Pain Relief in Patients with Rheumatoid Arthritis, a Systematic Review
Rongqiang Zhang¹, Puwei Yuan², Jia Li³, Bo Dong¹, Wulin Kang³, Stephanie Hyon⁴, Raveendhara R. Bannuru⁵, William F. Harvey⁴ and Chenchen Wang⁴, ¹Shaanxi University of Chinese Medicine, Xianyang 712046, China, Xianyang, China, ²Shaanxi University of Chinese Medicine, Xianyang 712046, China, XianYang, China, ³Shaanxi University of Chinese Medicine, Xianyang, China, ⁴Rheumatology, Center of Integrative Medicine and Division of Rheumatology, Tufts Medical Center, Boston, MA, Boston, MA, ⁵Center of Integrative Medicine and Division of Rheumatology, Tufts Medical Center, Boston, MA, Boston, MA
Background/Purpose: Medical bugs, a term used to describe insects and arthropods for medical treatment, have been widely used in the past centuries for pain relief.…
Abstract Number: 450 • 2017 ACR/ARHP Annual Meeting
Disease Duration and Withdrawal of Biologic Agents Predict Radiological Progression in a Cohort of Rheumatoid Arthritis Patients in Latin America. a Real World Study
Rocio V. Gamboa-Cardenas^1,2, Manuel Ugarte-Gil³, Francisco Zevallos⁴, Mariela Medina⁴, Claudia Elera-Fitzcarrald⁴, Victor Pimentel-Quiroz⁴, Cristina Reategui-Sokolova⁴, Omar Sarmiento-Velasquez⁴, Zoila Rodriguez-Bellido⁴, José Alfaro⁴, Mariano Cucho-Venegas⁴, Cesar A. Pastor-Asurza⁴ and Risto Perich-Campos⁵, ¹Rheumatology, Hospital Guillermo Almenara, EsSalud, Lima, Peru, ²Universidad Nacional Mayor de San Marcos, Lima, Peru, ³Peru, GLADEL, Lima, Peru, ⁴Rheumatology, Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, ⁵Rheumatology, Hospital Guillermo Almenara Irigoyen, Lima, Peru
Background/Purpose: Optimal management of Rheumatoid Arthritis (RA) based in identification of patients with risk factors for Joint Damage (JD) progression, is a main strategy, but…
Abstract Number: 451 • 2017 ACR/ARHP Annual Meeting
A Matrix Risk Model for Prediction of Radiographic Progression in Early Rheumatoid Arthritis Based on Treatment Response at 3 Months
Pooneh S. Akhavan¹, Daming Li¹, Sahar Tabatabvakili¹ and Edward C. Keystone², ¹Mount Sinai Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada
Background/Purpose: The present study aimed to develop a matix to predict risk of radiographic progression in patients with early rheumatoid arthritis. The focus of this…
Abstract Number: 452 • 2017 ACR/ARHP Annual Meeting
Time to First Treatment Is Associated with a Refractory Course of Rheumatoid Arthritis
Manuel Bécède¹, Farideh Alasti², Lukas Haupt³, Lisa Hütter³, Andreas Kerschbaumer⁴, Uriel Landesmann¹, Gabriela Supp⁴, Josef S. Smolen^4,5 and Daniel Aletaha⁶, ¹Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ²Rheumatology, Medical University of Vienna, Vienna, Austria, ³Department of Medicine, Hietzing Hospital, Vienna, Austria, ⁴Medical University Vienna, Division of Rheumatology, Department of Internal Medicine III, Vienna, Austria, ⁵Department of Internal Medicine, Hietzing Hospital, Vienna, Austria, ⁶Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria
Background/Purpose: It is an ongoing matter of research, whether the course of rheumatoid arthritis (RA) can be altered by an early intervention, a concept historically…
Abstract Number: 453 • 2017 ACR/ARHP Annual Meeting
The Therapy with Tocilizumab Is Not Associated with Periarticular Demineralisation and Finger Joint Space Narrowing in Rheumatoid Arthritis
Alexander Pfeil¹, Ottar Gadeholt², Joachim Böttcher³, Diane Renz⁴, Peter Oelzner¹ and Gunter Wolf¹, ¹Department of Internal Medicine III, Jena University Hospital, Jena, Germany, ²Rheumatology/Immunology, Medical Clinic II, University Clinic Wuerzburg, Wuerzburg, Germany, ³Institut of Interventional and Diagnostic Radiology, SRH Waldklinikum Gera, Gera, Germany, ⁴Institute of Diagnostic and Interventional Radiology, Jena University Hospital, Jena, Germany
Background/Purpose: Digital X-ray Radiogrammetry (DXR) and Computer-Aided Joint Space Analysis (CAJSA) are established computer based techniques for the quantification of metacarpal bone mineral density and…
Abstract Number: 454 • 2017 ACR/ARHP Annual Meeting
Soluble Urokinase Plasminogen Activator Receptor (suPAR) Correlates with Disease Activity in Early Rheumatoid Arthritis and Reflects Joint Damage over Time
Helena Enocsson¹, Alf Kastbom¹, Tanja Lukic¹, Christopher Sjöwall², Thomas Skogh¹ and Jonas Wetterö¹, ¹Rheumatology, Division of Neuro and Inflammation Sciences, Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden, Linköping, Sweden, ²Department of Clinical and Experimental Medicine, Linköping University, Sweden, Linköping, Sweden
Background/Purpose: The urokinase plasminogen activator receptor (uPAR) is expressed on various cell types and plays important roles in proteolysis, migration and adhesion. Receptor shedding yields…
Abstract Number: 455 • 2017 ACR/ARHP Annual Meeting
Analysis of Real-World Treatment Patterns in a Matched Sample of Rheumatology Patients with Continuous Infliximab Therapy or Switched to Biosimilar Infliximab
Lorie A. Ellis¹, Ismail Simsek², Lin Xie³, Adesuwa Ogbomo³, Dennis Parenti⁴, Kavitha Goyal⁴ and Yusuf Yazici⁵, ¹Janssen HECOR Immunology, Horsham, PA, ²Guven Hospital, Ankara, Turkey, ³STATinMED Research Inc., Ann Arbor, MI, ⁴Janssen Scientific Affairs, LLC, Horsham, PA, ⁵New York University School of Medicine, New York, NY
Background/Purpose: Biosimilar infliximab (CT-P13) was first approved in Europe in 2013.This study compared treatment (tx) patterns of Turkish pts with a diagnosis of rheumatoid arthritis(RA)…
Abstract Number: 456 • 2017 ACR/ARHP Annual Meeting
Time from First Symptom Onset to First Advanced Therapy Amongst RA Patients in Latin America
Ivanio Pereira¹, Valderilio F Azevedo², Wilson Bautista-Molano³, Julio Casasola⁴, Generoso Guerra⁵, David Vega-Morales⁶, Enrique R Soriano⁷, Diana Rocio Gil⁸, José Antonio Maldonado-Cocco⁹, Leandro Aldunate¹⁰ and Steve Lobosco¹¹, ¹Rheumatology, Universidade Federal de Santa Catarina, Hospital Universitário, Divisão de Reumatologia.Brazil, Florianopolis, Brazil, ²Adjunct Professor of Rheumatology, Federal University of Paraná; Brazil, Curitiba, Brazil, ³School of Medicine, Universidad Militar Nueva Granada and Rheumatology Department Hospital Militar. Colombia, Bogotá, Colombia, ⁴Rheumatology, Hospital General de Mexico, Mexico, Mexico, ⁵Centro Médico Paitilla Internal Medicine and Rheumatology Department. Panama, Panama City, Panama, ⁶Universidad Autónoma de Nuevo León. Rheumatology Service, Internal Medicine Department, Hospital Universitario "Dr. José Eleuterio González". Mexico, Monterrey, Mexico, ⁷Argentina, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁸ART Medica - Hospital Universitario Mayor MEDERI Internal Medicine and Rheumatology. Colombia., Bogota, Colombia, ⁹Buenos Aires University, Consulting Professor of Rheumatology, Buenos Aires University. Argentina, Buenos Aires, Argentina, ¹⁰Immunology, Janssen Latin America, Buenos Aires, Argentina, ¹¹Adelphi, Immunology Director- Adelphi Group, Manchester, United Kingdom
Background/Purpose: To understand the RA patient pathway in Latin America from first symptom onset; including time to diagnosis and to first advanced treatment. Methods: Data…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].